CN102872130B - Application of Houttuynoid D in drug for preventing or treating renal fibrosis - Google Patents
Application of Houttuynoid D in drug for preventing or treating renal fibrosis Download PDFInfo
- Publication number
- CN102872130B CN102872130B CN201210419498.6A CN201210419498A CN102872130B CN 102872130 B CN102872130 B CN 102872130B CN 201210419498 A CN201210419498 A CN 201210419498A CN 102872130 B CN102872130 B CN 102872130B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- renal fibrosis
- preventing
- drug
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ROCYDQPSKYPRJK-KXDBBDCJSA-N 2-[3,4-dihydroxy-2-(2-oxoundecyl)phenyl]-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound CCCCCCCCCC(=O)CC1=C(O)C(O)=CC=C1C1=C(O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 ROCYDQPSKYPRJK-KXDBBDCJSA-N 0.000 title claims abstract description 58
- 201000002793 renal fibrosis Diseases 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 229940079593 drug Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 14
- 241000700159 Rattus Species 0.000 description 11
- 102000016359 Fibronectins Human genes 0.000 description 7
- 108010067306 Fibronectins Proteins 0.000 description 7
- 206010016654 Fibrosis Diseases 0.000 description 7
- 230000004761 fibrosis Effects 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 5
- 229960002591 hydroxyproline Drugs 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 5
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 230000003602 anti-herpes Effects 0.000 description 4
- 240000000691 Houttuynia cordata Species 0.000 description 3
- 235000013719 Houttuynia cordata Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229930190556 houttuynoid Natural products 0.000 description 3
- 210000000626 ureter Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- 101000693993 Homo sapiens Sodium channel protein type 4 subunit alpha Proteins 0.000 description 2
- 208000007599 Hyperkalemic periodic paralysis Diseases 0.000 description 2
- 102100027195 Sodium channel protein type 4 subunit alpha Human genes 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229960004530 benazepril Drugs 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002665 bowman capsule Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of Houttuynoid D in preparing a drug for preventing or treating renal fibrosis. The use of Houttuynoid D in preparing the anti-renal fibrosis drug involved in the invention is disclosed for the first time; as the framework type of Houttuynoid D is a brand new framework type and Houttuynoid D has an unexpectedly high inhibition activity for the renal fibrosis without possibility of giving any implication by other compounds, Houttuynoid D has outstanding substantive features; and simultaneously, the application of Houttuynoid D for preventing the renal fibrosis apparently has obvious progress.
Description
Technical field
The present invention relates to a kind of new medicine use, relate to particularly the application of Houttuynoid D in the medicine of preparation treatment or preventing renal fibrosis.
Background technology
Renal fibrosis (comprising kidney region fibrosis and glomerular sclerosis) is the main pathological basis of the kidney damage final stage that causes of a variety of causes, renal fibrosis mechanism is comparatively complicated, relevant with many factors, wherein main and the celliferous propagation of extracellular matrix cell and activation, vaso-active substance, cytokine and extracellular matrix conversion are unbalance relevant, so kidney region fibrosis is almost the common pathway that former or secondary kidney disease proceed to end stage renal failure.
The compound H outtuynoid D the present invention relates to is one and within 2012, delivers (Chen, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), it is open first that purposes for the Houttuynoid D the present invention relates in preparation treatment or preventing renal fibrosis medicine belongs to, because framework types belongs to brand-new framework types, and it suppresses active unexpectedly strong for renal fibrosis, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, for the control of renal fibrosis, obviously there is significant progress simultaneously.
Summary of the invention
The invention provides the application of Houttuynoid D in the medicine of preparation prevention or treatment renal fibrosis.
Described compound H outtuynoid D structure is as shown in formula I:
The purposes of the Houttuynoid D the present invention relates in preparation treatment or preventing renal fibrosis medicine belongs to open first, because framework types belongs to brand-new framework types, and it suppresses active unexpectedly strong for renal fibrosis, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, for the control of renal fibrosis, obviously there is significant progress simultaneously.
The specific embodiment
The preparation method of compound H outtuynoid D involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid D tablet involved in the present invention:
Get 20 and digest compound Houttuynoid D, add 180 grams of conventional adjuvants preparing tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound H outtuynoid D capsule involved in the present invention:
Get 20 and digest compound Houttuynoid D, add the conventional adjuvant of preparing capsule as 180 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
The impact of test Houttuynoid D on Rats Undergoing Unilateral Urethral Ligation kidney region fibrosis
1.1 material
Benazepril, Novartis Pharma AG produces; Hydroxyproline (HYP) test kit, biotech firm is built up in Nanjing; Fibronectin (FN) test kit is purchased from Shanghai institute of Biological Products.
Laboratory animal: regular grade Wistar rat, male, body weight 150-200g, SD rat.
1.2 test methods and result
90 of rats, random point 9 groups, it is sham operated rats, model group, benazepril gavage 10mg/kg group, Houttuynoid D intravenous injection 2.5 mg/kg groups, Houttuynoid D intravenous injection 5 mg/kg groups, Houttuynoid D intravenous injection 25 mg/kg groups, Houttuynoid D gavage 5mg/kg group, Houttuynoid D gavage 10mg/kg group, Houttuynoid D gavage 50mg/kg group, animal feeding 1 week, each rat with 10% chloral hydrate 3.0mL/kg intraperitoneal injection of anesthesia after, by on fixing Rat Right lateral position and operating-table, after cropping, use iodine tincture, 75% alcohol disinfecting field of operation, row left side abdomen otch, successively cut skin, each layer of muscle and stomach wall, expose and separate left side ureter, sham operated rats is only cut abdominal cavity free left side ureter, but not ligation and cutting off, other are 4-0 silk thread ligation twice for each group rat, upper one ligation point is positioned at left inferior pole of kidney level, then at twice ligation point, cut off ureter, layer-by-layer suture, after postoperative 10 days 10% chloral hydrate anesthesia, put to death each treated animal, get blood, press Fibronectin and measure explanation mensuration explanation fiber connexin (FN).Normal saline is left and taken left kidney after lavation repeatedly, and nephridial tissue is fixed through 4% paraformaldehyde buffer.Cut appropriate nephridial tissue, by the explanation of hydroxyproline kit measurement, measure hydroxyproline.
Routine pathology is learned and is examined 1. perusal: sham operated rats kidney color is scarlet, shows smoothly, and peplos gloss, without adhesion.Other each group Kidney Volumes increase, and color is pale, shows to be graininess, similar human body branny kidney, the adhesion of a few regions kidney peplos.2. light microscopy checking: sham operated rats nephron result is clear, glomerular capsule is without expansion or cell infiltration.The large stretch of renal tubular necrosis of model control group, the hyperplasia of kidney interstitial fibers, tubular ectasia, inside has a large amount of brown color shading materials or the downright bad epithelial cell coming off, glomerule decreased number, part glomerule fibrosis and with the adhesion of bowman's capsule wall, blister cavities disappears.Administration respectively organizes pathological changes and model control group is similar, but all has morphology in various degree to improve, and especially with the heavy dose of each group of Houttuynoid D gavage significantly, relatively has notable difference with model control group.
The impact of table 1 Houttuynoid D on Rats Undergoing Unilateral Urethral Ligation kidney region fibrosis
* p<0.05, * * p<0.01, compares with model group
Each group of FN, HYP are carried out to T check.The results are shown in Table 1, Houttuynoid D intravenous injection 5 mg/kg groups, Houttuynoid D intravenous injection 25 mg/kg groups, Houttuynoid D gavage 10mg/kg group, Houttuynoid D gavage 50mg/kg group reduce FN, HYPP level (with model control group comparison, P<0.05 or 0.01).
Conclusion: Houttuynoid D can significantly reduce the rising of kidney region fibrosis FN, HYPP level, suppresses kidney region fibrosis, can be used for preparing anti-renal fibrosis medicine.
Claims (1)
- The application of 1.Houttuynoid D in the medicine of preparation treatment or preventing renal fibrosis, described compound H outtuynoid D structure as formula Ishown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210419498.6A CN102872130B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid D in drug for preventing or treating renal fibrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210419498.6A CN102872130B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid D in drug for preventing or treating renal fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872130A CN102872130A (en) | 2013-01-16 |
| CN102872130B true CN102872130B (en) | 2014-04-16 |
Family
ID=47473801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210419498.6A Active CN102872130B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid D in drug for preventing or treating renal fibrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872130B (en) |
-
2012
- 2012-10-27 CN CN201210419498.6A patent/CN102872130B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata;Shao-Dan Chen, et al.;《ORGANIC LETTERS》;20120313;第14卷(第7期);1772-1775 * |
| Shao-Dan Chen, et al..Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata.《ORGANIC LETTERS》.2012,第14卷(第7期),1772-1775. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872130A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101095668B (en) | Application of rosmarinic acid in the preparation of medicines for treating or preventing liver fibrosis and kidney fibrosis | |
| CN105287546A (en) | Use of Virosaines B in preparation of drug for treating and preventing renal fibrosis | |
| CN102872130B (en) | Application of Houttuynoid D in drug for preventing or treating renal fibrosis | |
| CN102861072B (en) | Application of Houttuynoid A in medicine for treating or preventing renal fibrosis | |
| CN102861063B (en) | Application of Houttuynoid C in medicine for treating or preventing renal fibrosis | |
| CN103585149B (en) | Application of Nitrosporeusines A in medicines for treating and preventing renal fibrosis | |
| CN102861085B (en) | Application of Houttuynoid E in medicine for treating or preventing renal fibrosis | |
| CN107854461A (en) | Apigenin is preparing the application in treating and preventing kidney fibrosis medicine | |
| CN102872042B (en) | Application of Gypensapogenin B in medicaments for treating or preventing renal fibrosis | |
| CN104188978A (en) | Application of O-(tetrahydropyrrole) ethyl derivative of cleistanthus sumatranus ketone in preparation of medicine for treating or preventing renal fibrosis | |
| CN106265691A (en) | Friedolanostanes application in preparation treats and prevents renal fibrosis medicine | |
| CN103251603A (en) | Application of Myriberine A in preparation of medicines for treating and preventing renal fibrosis | |
| CN105125568A (en) | Medicine for treating and preventing renal fibrosis and application of medicine | |
| CN103127089A (en) | Application of Eryngiolide A in medicines curing or preventing kidney fibrosis | |
| CN103599095B (en) | The application of Hippolachnin A in treatment and preventing renal fibrosis medicine | |
| CN103356659B (en) | The application of Chukrasone A in the medicine preparing treatment or preventing renal fibrosis | |
| CN105395541A (en) | Applications of Perovskone B in preparation of medicines treating or preventing renal fibrosis | |
| CN103585153B (en) | Use of Caesanines D in drugs for treating and preventing renal fibrosis | |
| CN103520181B (en) | The application of Phyllanthoid A in preparation treatment and preventing renal fibrosis medicine | |
| CN103462992B (en) | Application of Aphanamgrandiol A in preparation of medicaments for treating and preventing renal fibrosis | |
| CN102872083A (en) | Application of Houttuynoid B in medicines for treating or preventing renal fibrosis | |
| CN103356569A (en) | Application of Sarcaboside B in medicine used for treating or preventing renal fibrosis | |
| CN103120677A (en) | Application of Aphanamixoid A in medicine for treating or preventing renal fibrosis | |
| CN103463005B (en) | Application of racemosins A in preparation of medicine treating or preventing renal fibrosis | |
| CN103381159A (en) | Applications of Chukrasone B in medicines used for treating or preventing renal fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QIDONG TIANFEN ELECTRIC TOOL TECHNOLOGY INNOVATION Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141128 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226241 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141128 Address after: Qidong City, Jiangsu province 226241 Nantong lvsigang Tianfen electric tools trade city comprehensive building Patentee after: Qidong Tianfen Electric Tool Technology Innovation Center Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |